Flurbiprofen Lozenges


Flurbiprofen lozenges have been approved in many countries since 2009 (Strepsils Dolo, formerly Strepsils). In other countries, the drug has been on the market for years. Generics were approved for the first time in 2016.

Structure and properties

Flurbiprofen (C15H13FO2, Mr = 244.2 g/mol) is a racemate and exists as a white crystalline powder that is practically insoluble in water. Like ibuprofen, flurbiprofen belongs to the propionic acid derivative group and is a fluorinated biphenyl derivative.


Flurbiprofen (ATC M01AE09) is a nonsteroidal anti-inflammatory drug with anti-inflammatory and analgesic effects. It does not anesthetize and is not a local anesthetic. The effect is delayed after more than half an hour and lasts for a long time, during 2-3 hours. Flurbiprofen is absorbed in the digestive tract.


For short-term symptomatic treatment of painful inflammation of the pharyngeal mucosa (e.g., sore throat).


According to the package leaflet. The lozenge is dissolved slowly in the mouth.


  • Hypersensitivity, including to other NSAIDs
  • Last third of pregnancy
  • Children under 12 years
  • Gastrointestinal ulcers, gastrointestinal bleeding, severe colitis, bleeding or hematopoietic disorders.

For complete precautions, see the drug label.


Drug-drug interactions are possible with antithrombotics, diuretics, antihypertensives, digoxin, and sulfonylureas, among others.

Adverse effects

The most common adverse effects include: Warm sensation, tingling sensation, and burning sensation in the mouth, headache, dizziness, sleep disturbance, nausea, diarrhea, ulceration of the oral mucosa, dry mouth, indigestion, vomiting, flatulence, abdominal pain.